Therapeutic RNA Strategies for Chronic Obstructive Pulmonary Disease

Trends Pharmacol Sci. 2020 Jul;41(7):475-486. doi: 10.1016/j.tips.2020.04.007. Epub 2020 May 17.

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation with persistent respiratory symptoms. Current therapeutics for COPD are largely borrowed from the drug armamentarium for the treatment of asthma, which has different pathophysiological mechanisms from COPD. COPD has been linked to dysregulated expression of mRNAs and noncoding (nc)RNAs including miRNAs, PIWI-interacting (pi)RNAs, long noncoding (lnc)RNAs, and circular (circ)RNAs. This review highlights and discusses some recent advances towards development of RNA therapeutics for COPD.

Keywords: antagomir; antisense oligonucleotide; circular RNA; long noncoding RNA; miRNA; siRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Asthma* / therapy
  • Humans
  • Lung
  • MicroRNAs* / therapeutic use
  • Pulmonary Disease, Chronic Obstructive* / therapy
  • RNA, Messenger

Substances

  • MicroRNAs
  • RNA, Messenger